Drug Trial Radar · NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
460
Planned (sponsor's estimate)
Start
Jul 1, 2024
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jun 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Conditions
- Metastatic Solid Tumor
- Recurrent Solid Tumor
- Advanced Solid Tumor
- Urinary Bladder Neoplasm
- Triple Negative Breast Cancer
- Non-small Cell Lung Cancer
- Esophageal Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Cervical Cancer
- Head and Neck Squamous Cell Carcinoma
- Prostate Cancer
- Renal Pelvis Cancer
- Bladder Cancer
Interventions
LY4052031Drug
Intravenous
PembrolizumabDrug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031Time frame: Cycle 1 (21 Days)
- Phase 1b: To assess the antitumor activity of LY4052031 as monotherapy or in combination with pembrolizumab: Overall response rate (ORR)Time frame: Up to Approximately 48 Months or 4 Years
Locations
40 sites in 8 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California · Recruiting
University of California, San Diego (UCSD) - Moores Cancer Center
La Jolla, California · Recruiting
UCLA Department of Medicine-Hematology/Oncology
Los Angeles, California · Recruiting
Sarah Cannon Research Institute at HealthOne
Denver, Colorado · Recruiting
Florida Cancer Specialists and Research Institute
St. Petersburg, Florida · Completed
Emory University
Atlanta, Georgia · Recruiting
University of Chicago Hospital
Chicago, Illinois · Recruiting
IU Simon Cancer Center
Indianapolis, Indiana · Not yet recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
START Midwest Cancer and Hematology Centers of W Michigan
Grand Rapids, Michigan · Recruiting
Washington University School of Medicine in St. Louis
St Louis, Missouri · Recruiting
NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute)
New York, New York · Recruiting
NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute)
New York, New York · Not yet recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Columbia University Irving Medical Center
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
Tennessee Oncology PLLC
Nashville, Tennessee · Not yet recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas · Recruiting
University of Utah - Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
St Vincent's Hospital
Darlinghurst, Australia · Recruiting
Linear Clinical Research
Nedlands, Australia · Recruiting
Beijing Cancer hospital
Beijing, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, China · Recruiting
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China · Recruiting
Institut Gustave Roussy (Igr)
Villejuif, France · Recruiting
National Cancer Center Hospital
Chūōku, Japan · Recruiting
National Cancer Center Hospital East
Kashiwa, Chiba, Japan · Recruiting
The Cancer Institute Hospital of JFCR
Kōtō City, Japan · Recruiting
Aichi Cancer Center Hospital
Nagoya, Japan · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Catalan Institute of Oncology Duran i Reynals Hospital
Barcelona, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Madrid Norte Sanchinarro
Madrid, Spain · Recruiting
Hospital Universitario Virgen Del Rocio
Seville, Spain · Recruiting
St Bartholomew's Hospital
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.